I know others have mentioned previously, but this is a recent article. I believe it could be a long way off as oncology is the focus, but I don't know why Kazia wouldn't be approached for a trial related to autism.
Targeting PI3K-AKT/mTOR signaling in the prevention of autism - ScienceDirect